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Incidence trends for childhood type 1 diabetes in Europe 
during 1989–2003 and predicted new cases 2005–20: 
a multicentre prospective registration study
Christopher C Patterson, Gisela G Dahlquist, Eva Gyürüs, Anders Green, Gyula Soltész,and the EURODIAB Study Group
Summary
Background The incidence of type 1 diabetes in children younger than 15 years is increasing. Prediction of future 
incidence of this disease will enable adequate fund allocation for delivery of care to be planned. We aimed to establish 
15-year incidence trends for childhood type 1 diabetes in European centres, and thereby predict the future burden of 
childhood diabetes in Europe.
Methods 20 population-based EURODIAB registers in 17 countries registered 29 311 new cases of type 1 diabetes, 
diagnosed in children before their 15th birthday during a 15-year period, 1989–2003. Age-speciﬁ c log linear rates of 
increase were estimated in ﬁ ve geographical regions, and used in conjunction with published incidence rates and 
population projections to predict numbers of new cases throughout Europe in 2005, 2010, 2015, and 2020.
Findings Ascertainment was better than 90% in most registers. All but two registers showed signiﬁ cant yearly 
increases in incidence, ranging from 0·6% to 9·3%. The overall annual increase was 3·9% (95% CI 3·6–4·2), and the 
increases in the age groups 0–4 years, 5–9 years, and 10–14 years were 5·4% (4·8–6·1), 4·3% (3·8–4·8), and 2·9% 
(2·5–3·3), respectively. The number of new cases in Europe in 2005 is estimated as 15 000, divided between the 
0–4 year, 5–9 year, and 10–14 year age-groups in the ratio 24%, 35%, and 41%, respectively. In 2020, the predicted 
number of new cases is 24 400, with a doubling in numbers in children younger than 5 years and a more even 
distribution across age-groups than at present (29%, 37%, and 34%, respectively). Prevalence under age 15 years is 
predicted to rise from 94 000 in 2005, to 160 000 in 2020.
Interpretation If present trends continue, doubling of new cases of type 1 diabetes in European children younger than 
5 years is predicted between 2005 and 2020, and prevalent cases younger than 15 years will rise by 70%. Adequate 
health-care resources to meet these children’s needs should be made available.
Funding European Community Concerted Action Program.
Introduction
Wide variation in incidence of type 1 diabetes in children 
younger than 15 years has been well characterised by 
registry reports from the EURODIAB study group within 
Europe1 and the DIAMOND project group worldwide.2 
The DIAMOND project also analysed trends by continent 
in the period 1990–99, and showed increases in every 
region except Central America and the West Indies. In 
Europe, where numbers of cases are large enough to 
enable useful comparisons of rises in incidence in 
diﬀ erent age-groups, evidence shows that increases in 
incidence were highest in the youngest age-group.3 
Furthermore, analysis of EURODIAB registration data 
for 1989–98 in regions within Europe shows that rates of 
increase diﬀ ered signiﬁ cantly and were highest in central 
and eastern European countries.1
The emergence of type 2 diabetes in children and 
adolescents has received much attention, but this issue 
should not be allowed to overshadow the rapid rises in 
type 1 diabetes in this age-group. Although in a few 
countries most cases in children will be type 2 diabetes,4 
in most European countries type 1 diabetes is, and will 
probably remain, the predominant form of this disease.5 
Prediction of future numbers is important to facilitate 
plans for the delivery of care and treatment of 
complications that might arise in early adulthood in 
these children. We aim to document trends in incidence 
of childhood type 1 diabetes in Europe during 1989–2003, 
and to use this information to predict the future burden 
of this disease in European children.
Methods
Inclusion criteria and region selection
Case inclusion criteria were as previously described for 
the EURODIAB registers6—new diagnoses of type 1 
(insulin-dependent) diabetes mellitus in children 
younger than 15 years who were usually resident in the 
geographically deﬁ ned region. Completeness of regis-
tration was estimated separately for three 5-year periods 
by capture-recapture methods,7 for which independent 
primary and secondary sources of ascertainment are 
needed. In most centres, the primary sources of 
ascertainment were hospital records or notiﬁ cations by 
paediatricians and family doctors, whereas secondary 
sources varied depending on local circumstances, and 
included social insurance schemes, diabetes associations, 
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and prescription data. In common with many uses of 
capture-recapture methods in epidemiology, neither the 
assumption of source independence nor the assumption 
of equal probability of capture of each case by any given 
source is easily veriﬁ able, so our estimates can provide 
only an imperfect estimate of completeness. Likely to be 
less sensitive to these assumptions is the comparison of 
each centre’s completeness estimate during the three 
5-year periods, which is especially important when 
incidence trends are being investigated.
Annual estimates of population in each centre’s 
geographically deﬁ ned area were used as denominators 
for calculation of standardised incidence rates. 
Standardisation was by the direct method with a standard 
population consisting of equal numbers of children in 
each of six subgroups deﬁ ned by age-group (0–4 years, 
5–9 years, and 10–14 years) and sex. To provide 
appropriate numbers of cases for the estimation of 
trends in each of these six subgroups, Europe was 
divided into ﬁ ve regions. Regions were deﬁ ned by three 
factors—geography, incidence rate, and numbers of 
registered cases. The Scandinavian centres (Denmark, 
Finland, Norway, and Sweden) formed a natural north 
region of very high incidence, and the three UK centres 
formed a northwest region of high incidence. An 
arbitrary target ﬁ gure of about 5000 registered cases for 
each centre was chosen. Construction of the three other 
regions—each of countries with roughly homogeneous 
incidence rates—was largely guided by results from our 
previous report, which included data from 44 centres 
representing most countries of Europe.3 The west region 
consisted of Spain, Luxembourg, Belgium, and two 
German centres; the central region comprised the Czech 
Republic, Austria, and Slovenia; and the East region 
consisted of Lithuania, Poland, Slovakia, Hungary, and 
Romania (ﬁ gure 1). 
Statistical analysis 
Poisson regression was used to investigate trends in 
incidence within centres. This method speciﬁ es that 
factors have an additive eﬀ ect on a logarithmic incidence 
scale (or equivalently, a multiplicative eﬀ ect on the 
incidence scale). For each centre, a base model with 
terms for age-group (0–4 years, 5–9 years, and 10–14 years), 
sex, and age-group by sex interaction was ﬁ tted. Addition 
of a linear term for calendar year to this model provided a 
test for trend with time in the centre that took account of 
any changes in population age structure during the 
period, and gave an estimate of the annual percentage 
rise together with 95% conﬁ dence limits. A test for 
departure from log-linear time trend (ie, a check for 
deviation from linearity) was obtained by a likelihood-ratio 
test comparing the linear trend model with a general 
model that allowed for any pattern of diﬀ erence between 
the years. Further models incorporating interaction 
terms were used to test for diﬀ erences in linear time 
trends between sexes and between age-groups within 
each centre. 
Furthermore, Poisson regression was used to compare 
trends in incidence in the ﬁ ve regions. For this analysis, 
the base model contained terms for sex, age-group, 
region, and all possible interactions. This base model, 
therefore, speciﬁ ed diﬀ erent age and sex-speciﬁ c 
incidence rates in each region. Addition of a linear term 
in calendar year provided a test for time trends that took 
the form of a single annual percentage rise common to 
both sexes and all age-groups and regions. Interactions 
of this term with sex, age, and region tested for diﬀ erent 
time trends in the sexes, in diﬀ erent age-groups, and 
regions, respectively. High order interactions between 
these terms and the linear term in calendar year provided 
tests for patterns of further complexity (eg, the age by sex 
by year interaction tested for diﬀ erent patterns of 
age-speciﬁ c rises in incidence in boys and girls). 
Likelihood-ratio χ² tests were used to compare ﬁ t of 
nested models with tests undertaken at the 5% signiﬁ cance 
level. Akaike’s information criterion was also used to aid 
model selection. A goodness-of-ﬁ t test, obtained as a 
likelihood-ratio test comparing the ﬁ t of each model with 
that of a saturated model that perfectly predicted observed 
numbers of cases, was used to assess model ﬁ t and to 
Figure 1: 20 EURODIAB centres in 17 countries split into regions with homogeneous incidence rates
Purple=north region, four centres and 4717 cases. Pink=north west region, three centres and 5167 cases. 
Orange=west region, ﬁ ve centres and 6673 cases. Green=central region, three centres and 6198 cases. Blue=east 
region, ﬁ ve centres and 6556.
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check for overdispersion. A signiﬁ cant goodness-of-ﬁ t 
test shows that a model ﬁ ts the data poorly. All models 
were ﬁ tted by use of Stata 8.
Estimates of new cases in 2005 and predictions for 
future new cases were made by extrapolation of base-year 
incidence rates, with the annual percentage increase in 
incidence in each age-group in the ﬁ ve regions estimated 
from the Poisson regression analysis. Prevalence ﬁ gures 
were derived from cumulated incidence rates. Extra-
polated rates were then applied to the EUROSTAT 2005 
population estimates8 and the UN medium variant 2010, 
2015, and 2020 population projections.9 This approach 
assumes that future annual rates of increase are equal to 
those derived from the Poisson regression analysis of 
EURODIAB centre rates in 1989–2003. Base-year in-
cidence rates used for the extrapolation in each country 
were published rates for the most recently available 
5-year period (webappendix p 1). Nationwide estimates 
were used when available. When the reported rates were 
based on fewer than 150 cases in the 5-year period, a 
period of 10 years or 15 years was preferred to obtain 
more stable rates on which to base extrapolations. 
Role of the funding source
The funding source played no part in the study design, 
collection, analysis, and interpretation of data, writing of 
the report, or in the decision to submit the paper for 
publication. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results 
Table 1 shows the total numbers of cases registered during 
1989–2003 in each of the 20 centres and the 
age-standardised incidence rates in the three 5-year 
periods. Most centres maintained greater than 
90% completeness of ascertain ment in all three periods, 
with many achieving in excess of 95%. For all but two 
centres, the estimated annual increases in incidence were 
signiﬁ cant. Use of a log linear trend to summarise these 
data was considered appropriate because the test for 
departure from linear trend reached signiﬁ cance in only 
one of the 20 centres. Figure 2 shows an inverse association 
(Spearman rank correlation, rS=–0·52, p=0·02) between 
the rise in incidence rate during the 15-year period and the 
average rate during the same period.
Further Poisson regression modelling of interactions 
provided little evidence of any diﬀ erence in rates of 
increase between the sexes, the comparison reaching sig-
niﬁ cance in only one of 20 centres. By contrast, in six 
centres (Austria, Czech Republic, Finland, Baden 
Württemberg in Germany, Poland, and Yorkshire in the 
UK) (table 1) rates of increase diﬀ ered signiﬁ cantly 
between age-groups—in every case the lowest rate of 
increase was recorded in the oldest age-group. Many other 
centres showed the same pattern though the comparison 
between age-groups did not attain signiﬁ cance.
The overall annual increase for all centres was estimated 
as 3·9% (95% CI 3·6–4·2), with corresponding rises in 
the 0–4 year, 5–9 year, and 10–14 year age ranges of 
5·4% (4·8–6·1), 4·3% (3·8–4·8), and 2·9% (2·5–3·3), 
respectively. To help characterise geographical diﬀ erences 
in these patterns, the 20 centres were aggregated into 
ﬁ ve regions (giving a dataset of 2 sexes×3 age-groups
×5 regions×15 years=450 observations). Poisson regres-
sion analyses of this dataset are summarised in table 2. 
First, the base model was ﬁ tted (line 1), deﬁ ning a 
separate set of six age-speciﬁ c and sex-speciﬁ c rates in 
each region but assuming that these rates did not change 
in the 15 years. A single log linear term for year, 
representing a common trend between sexes, age-groups, 
and regions was highly signiﬁ cant (line 2), but the 
resultant model failed to provide an adequate ﬁ t to the 
data (goodness-of-ﬁ t test p<0·0001). When this trend was 
allowed to diﬀ er between age groups through addition of 
a term representing an interaction between year and age 
group (line 3), the likelihood-ratio test for the added term 
was signiﬁ cant (p<0·0001), indicating diﬀ erent rates of 
change over time in diﬀ erent age-groups. 
Addition of an interaction between year and sex was 
not signiﬁ cant (line 4), but interaction between year, age, 
and sex was signiﬁ cant (line 5; p=0·03), which suggests 
Region Number 
of cases
Standardised 
incidence* 
per 100 000 
(P1; P2; P3†)
Completeness of 
ascertainment 
(P1; P2; P3)
Increase per year 
(95% CI)‡
Austria Whole nation 2215 9·0; 9·9; 13·3 99·6%; 100%; 97·6% 4·3% (3·3 to 5·3)
Belgium Antwerp 318 10·9 ; 12·9; 15·4 99·2%; 97·9%; 94·8% 3·1% (0·5 to 5·8)
Czech Republic Whole nation 3479 8·7; 11·7; 17·2 100%; 99·8%; 98·7% 6·7% (5·9 to 7·5)
Denmark Four counties 657 17·0; 16·3; 22·9 99·8%; 99·5%; 100% 3·2% (1·4 to 5·1)
Finland Two regions 1306 39·9; 50·0; 52·6 100%; 100%; 100% 2·7% (1·4 to 4·0)
Germany Baden 
Württemberg
3362 11·0; 13·0; 15·5 95·6%; 98·3%; 100% 3·7% (2·9 to 4·5)
Germany Düsseldorf 922 12·5; 15·3; 18·3 92·8%; 97·9%; 95·4% 4·7% (3·1 to 6·3)
Hungary 18 counties 2152 8·8; 10·5; 11·5 97·9%; 94·9%; 95·5% 2·9% (1·9 to 3·9)
Lithuania Whole nation 996 7·3; 8·2; 10·3 100%; 100%; 100% 3·8% (2·2 to 5·3)
Luxembourg Whole nation 148 11·4; 12·3; 15·5 100%; 100%; 100% 2·4% (–1·4 to 6·3)
Norway 8 counties 1380 21·1; 20·5; 24·6 100%; 100%; 100% 1·3% (0·1 to 2·6)
Poland Katowice 1156 5·2; 7·9; 13·0 ·· ; 99·9%; ·· 9·3% (7·8 to 10·8)
Romania Bucharest 378 4·7; 6·1; 11·3 100%; 100%; 100% 8·4% (5·8 to 11·0)
Slovakia Whole nation 1874 8·2; 10·3; 13·6 100%; 100%; 100% 5·1% (4·0 to 6·3)
Slovenia Whole nation 504 7·9; 9·2; 11·1 100%; 100%; 100% 3·6% (1·5 to 5·7)
Spain Catalonia 1923 12·4; 13·6; 13·0 93·5%; 84·6%; 97·6% 0·6% (–0·4 to 0·6)
Sweden Stockholm 
county
1374 25·8; 25·6; 34·6 100%; 100%; 100% 3·3% (2·0 to 4·6)
UK Northern 
Ireland
1435 20·0; 24·7; 29·8 98·8%; 99·9%; 99·6% 4·2% (3·0 to 5·5)
UK Oxford 1615 17·1; 21·7; 22·4 ·· ; 95·3%; 90·2% 2·2% (1·1 to 3·4)
UK Yorkshire 2117 16·0; 19·7; 23·3 99·3%; 99·5%; 99·7% 3·6% (2·6 to 4·6)
··=data not available. *Standard population has six age–sex subgroups of equal size. †P1=1989–93; P2=1994–98; 
P3=1999–2003. ‡Derived from the coefficient for a term in the Poisson regression model representing year.
Table 1: Summary information for 20 EURODIAB centres with registration data 
See Online for webappendix
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that diﬀ erences in trends between age-groups depended 
on sex. Girls showed faster rates of increase in incidence 
of type 1 diabetes in the 5–9 year age-group and slower 
rates in the 10–14 year age-group than did boys. When 
the trend was allowed to diﬀ er between regions through 
addition of a year by region interaction (line 6), this 
interaction was signiﬁ cant (p<0·0001), showing diﬀ ering 
rates of rise in incidence in diﬀ erent regions. The 
goodness-of-ﬁ t tests show that line 6 was the simplest 
model, that provided an adequate ﬁ t to the data with no 
evidence of overdispersion. Since this model also gave 
the lowest Akaike information criterion, it was selected 
for prediction purposes. Further models specifying diﬀ er-
ences in trends between regions that varied between 
sexes and age groups (lines 7, 8, and 9) had non-signiﬁ cant 
likelihood-ratio tests.
The log linear trends obtained from the model in 
line 6 (table 2) are summarised in ﬁ gure 3. The rapid rise 
of type 1 diabetes in the youngest age-group in regions in 
central and east Europe (ﬁ gure 1) are especially striking. 
Of note is the tendency for rates in the diﬀ erent 
age-groups to converge over time in many regions. 
Smaller rises in incidence in girls compared with in boys 
aged 10–14 years were also observed.
Some countries, mainly in the eastern fringes of 
Europe, had no published age-speciﬁ c incidence rates for 
type 1 diabetes available. Belarus, the Russian Federation, 
Ukraine, Moldova, and Albania were, therefore, omitted 
from analysis of estimated new cases in 2005 and 
predicted numbers in 2010, 2015, and 2020. Predicted 
numbers were calculated by application of rates of 
increase (ﬁ gure 3) to the base rates (webappendix p 1). 
Results are summarised by age-group and sex in ﬁ gure 4 
(country by country data in webappendix p 3). The 
estimated number of new cases of type 1 diabetes in 
Europe in 2005 is 15 000, and this total is divided between 
the 0–4 years, 5–9 years, and 10–14 years age-groups in 
the ratio 24%, 35%, and 41%, respectively. 
By 2020, the predicted number of new cases is 24 400, 
but this change is not shared evenly between the age 
groups, with incidence of type 1 diabetes in the youngest 
age group expected to double in both sexes compared 
with a factor of 1·6 in boys and 1·3 in girls in the oldest 
age-group. On the basis of our predictions, we suggest 
that in 2020 the percentage distribution of new cases 
across the three age-groups will be more uniform at 
29% (0–4 years), 37% (5–9 years), and 34% (10–14 years), 
with the excess of new cases in the 5–9 year age range 
being most apparent in girls. Prevalent cases under age 
15 years are expected to rise from 94 000 in 2005, to 160 000 
in 2020 (country by country data in webappendix p 4).
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Figure 2: Inverse association between rate of incidence increase and average incidence 
Incidence rate on horizontal axis, plotted on a logarithmic scale. Spearman rank correlation coeﬃ  cient rs=–0·52, p=0·02.
Model Likelihood ratio test for last 
term (p value)
AIC Goodness of ﬁ t (p value)
1 Base model* 4095·2 <0·0001
2 Base model+Y <0·0001 3298·5 <0·0001
3 Base model+Y+Y•A <0·0001 3253·9 0·0007
4 Base model+Y+Y•A+Y•S 0·53 3255·5 0·0006
5 Base model+Y+Y•A+Y•S+Y•A•S 0·03 3252·8 0·0010
6 Base model+Y+Y•A+Y•S+Y•A•S+Y•R <0·0001 3171·6 0·37
7 Base model +Y+Y•A+Y•S+Y•A•S+Y•R+Y•R•A 0·13 3175·0 0·43
8 Base model+Y+Y•A+Y•S+Y•A•S+Y•R+Y•R•A+Y•R•S 0·79 3181·3 0·39
9 Base model+Y+Y•A+Y•S+Y•A•S+Y•R+Y•R•A+Y•R•S +Y•R•A•S 0·94 3194·4 0·33
Trends for data from 20 centres grouped into 5 regions. Model 6 is the most parsimonious model providing a reasonable ﬁ t, and it also has the smallest AIC value. AIC=Akaike 
Information Criterion. Model terms are: A=terms for age-groups 0–4, 5–9, and 10–14 years; S=term for sex; R=terms for region (or centre group); Y=term for linear trend 
across the 15 years; A•S=terms for the interaction between age-group and sex. *Base model=A+S+A•S+R+A•R+S•R+A•S•R.
Table 2: Summary of Poisson regression analyses of incidence trends
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Discussion
From review of worldwide epidemiology of childhood 
type 1 diabetes,10 we noted that Europe provides the most 
informative data about present incidence trends; European 
estimates of age-group-speciﬁ c annual increases have 
narrower CIs than do estimates from other continents, 
indicating greater precision. We have extended the analysis 
of European trends to conﬁ rm that the highest rates of 
increase, at least in relative terms, arise in the youngest 
age-groups. The most striking changes over time are 
observed in central and eastern European countries. These 
increases in countries with lower incidence result in a 
tendency for incidence rates in Europe to converge.
Although cohort eﬀ ects have been examined,11–16 results 
have been equivocal. Incorporation of cohort eﬀ ects in 
our model might have improved our ability to predict 
rates in the future, but a 15-year period is rather short for 
such an analysis, and the diﬃ  culties in separation of 
period and cohort eﬀ ects when the predominant pattern 
of change is one of linear increase are well recognised.17 
Notably, incidence of type 1 diabetes in young adults over 
age 15 years shows little evidence of rising,18,19 but a higher 
incidence in men than in women is widely reported in 
this age range.20 If type 1 diabetes really is shifting toward 
a younger age at diagnosis, lower incidence rates in 
women 15 years or older might help to explain the low 
rates of increase in girls in the 10–14 year age range seen 
in all ﬁ ve regions.
Our extrapolation of rates to predict numbers of new 
cases in future years assumes that log linear trends ﬁ tted 
to age-speciﬁ c incidence rates in the EURODIAB register 
data for 1989–2003 will continue into the future. Although 
we found no evidence of systematic departures from log 
linear trends, either in our centre-by-centre analysis or 
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Figure 3: Incidence rate increases by region
Points=observed annual rate. Lines=trends in rates predicted by the best ﬁ tting Poisson regression model.
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analysis of the ﬁ ve regions, this absence of evidence does 
not provide any guarantee that our assumption will be 
valid; moreover, brief periods of apparent stabilisation of 
rates have been reported.21,22 However, such periods 
appear to be transient, and the general trend in incidence 
continues to be upward in the long term. We have 
examined the likely consequences for incidence of type 1 
diabetes in Europe if our assumption of a log linear 
increase holds, and we predict numbers of new cases in 
children younger than 5 years old will double between 
2005 and 2020. Regional diﬀ erences in European 
incidence rates might become less pronounced, because 
low-incidence countries in eastern and central Europe 
have the most rapid rises in rates.
Our analysis gives no explanation for the time trends 
we have described, but the rapid changes over time 
clearly cannot be attributable to changes in prevalence of 
susceptibility genes. One suggestion is that need for 
genetic susceptibility has lessened over time because of 
heightened environmental pressure, which results in a 
raised disease progression rate—especially in individuals 
with protective HLA genotypes.23 Several hypotheses24–26 
based on analytical epidemiological studies have pointed 
to modern lifestyle habits as possible environmental 
factors, such as increased weight and height develop-
ment,27 and caesarean section deliveries,28 or reduced 
frequency of early infections.29 This notion accords with 
reported ecological associations between estimates of 
gross domestic product and incidence rate in European 
countries.30 Faster rates of increase in countries with low 
incidence rate—in particular eastern European 
countries—might be an expression of eﬀ ects of lifestyle 
factors, which are changing rapidly in these countries; 
therefore, convergence of incidence rates might reﬂ ect 
harmonisation of lifestyle-related risk factors in Europe.
The predicted rise in childhood type 1 diabetes in 
Europe during the next 20 years, and the raised proportion 
of cases diagnosed at younger ages than were before, 
could result in more cases presenting with ketoacidosis 
and needing hospital admission. More patients with 
severe diabetes complications presenting at younger ages 
than before are also likely, and appropriate care from 
diagnosis, and maintenance of good metabolic control 
are crucial for delay or prevention of these adverse 
complications.31 In the absence of any eﬀ ective means to 
prevent type 1 diabetes, European countries need to 
ensure appropriate planning of services and that 
resources are in place to provide high-quality care for the 
increased numbers of children who will be diagnosed 
with diabetes in future years.
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